Thalidomide Inhibits the Growth and Progression of Hepatic Epithelioid Hemangioendothelioma

Mascarenhas, Ranjan; Sanghvi, Amit N.; Friedlander, Lois; Geyer, Stanley J.; Beasley, H. Scott; Thiel, David H. Van

doi:10.1159/000082932

Cited by 59 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a novel alternative therapy targeting angiogenesis, for e.g. thalidomide or metronomic cyclophosphamide, has been found to be promising [12][13][14]. The 5-year survival rates for hepatic EHE patients with liver resection, chemotherapy or radiotherapy, and no treatment are 75%, 30% and 5% respectively [11].…”

Section: Discussionmentioning

confidence: 99%

Hepatic Epithelioid Hemangioendothelioma with Cecal Metastasis in a Natural Course: A Case Report

Chen¹,

Lai²

2016

J Cytol Histol

View full text Add to dashboard Cite

Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor of low malignant potential that occurs mostly in soft tissue. So far, only two cases of EHE involving the intestine have been recorded. Here, we describe a rare case of cecal EHE due to a subsequent metastasis from the primary liver tumor three years after initial diagnosis. A 74-year-old man had sudden onset of epigastralgia for 24 hours. The abdominal CT revealed an ileocecal mass with a small bowel obstruction, and extensive tumor involvement in the liver was noted. He received an emergent right hemicolectomy for relief of the ileus. Unfortunately, he expired four days later due to septic shock. The pathologic diagnosis of EHE prompted a molecular study for a WWTR1-CAMTA1 fusion. The Sanger sequencing results showed the fusion involved exon 4 of WWTR1 with exon 8 of CAMTA1. There is no standard treatment for hepatic EHE because of its rarity and variable clinical outcome. The decision on a treatment strategy should be individualized for each patient. Since the patient received supportive care only for the liver tumor, this case demonstrated a natural course of hepatic EHE with a survival of more than 3.3 years.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatic Epithelioid Hemangioendothelioma with Cecal Metastasis in a Natural Course: A Case Report

Chen¹,

Lai²

2016

J Cytol Histol

View full text Add to dashboard Cite

show abstract

“…Epithelioidhemangioendotheliomaisararemalignantvasculartumor,arisingintheendothelialliningofvessels.Themost commonlocationofaprimaryepithelioidhemangioendotheliomaistheliver,andinmanycasesthetumorismultifocalat the time of diagnosis so that liver resection or hepatectomy andtransplantationcouldbetheonlycurativeprocedureand theprocedureofchoiceevenincasesofextrahepaticdisease [4,5].Aprimarylocationinthekidneywithsurgicalexcision ofalocalizedtumorandanuneventfulfollow-uphasbeendescribedinonly1publication [1].Thalidomide,paclitaxeland doxorubicin,adriamycin,andinterferon-2-alphahaveallbeen reportedincasereportsassystemictherapiesforpatientswith epithelioid hemangioendothelioma [6][7][8][9], but with uncertain resultsgiventhesmallnumberofreports.…”

Section: Discussionmentioning

confidence: 99%

Epithelioid Hemangioendothelioma of the Kidney Treated with Sunitinib

Tolkach

Петров²,

Lerut³

et al. 2012

Onkologie

View full text Add to dashboard Cite

Background: Metastatic epithelioid hemangioendothelioma of the kidney is a rare malignant vascular tumor with a wide spectrum of behaviors. Case Report: We present the case of a 53-year-old male patient with tumor metastases which developed after radical nephrectomy. We describe the immunohistochemistry profile of the tumor and the successful long-term results of treatment with sunitinib, a multi-targeted tyrosine kinase inhibitor. Also, we discuss the rationale for using this type of medication based on immunohistochemistry results. Conclusion: To the best of our knowledge, this is the first reported case of metastatic renal epithelioid hemangioendothelioma treated successfully with sunitinib.

show abstract

“…Immunostaining with Factor VIII antigen or CD-34 antigen confirms the cell of origin. They are primarily treated surgically; adjunctive therapies like radiotherapy, chemotherapy and anti-angiogenic therapies (interferon-alpha and thalidomide) can be used in unresectable tumours [15] . Preoperative embolisation or sclerotherapy has been tried in giant lesions to reduce blood loss or improve resectability.…”

Section: Discussionmentioning

confidence: 99%

Large Pelvic Masses of Obscure Origin: Urologist’s Perspective

Kumar

Sarkar²,

Prasad³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Background: Large pelvic masses pose unique diagnostic and therapeutic challenges due to varied aetiology, paucity of characteristic imaging features, lack of therapeutic algorithms and surgical difficulties in resection inside the narrow confines of the pelvis with close proximity of vital structures. Methods: Records of 22 patients with large pelvic masses in the last six years were analysed. Their demographic and clinical features were noted, along with imaging features, preoperative biopsy, surgical procedure, intraoperative difficulties, complications, adjuvant therapy and outcome. Results: There were 14 men and 8 women with a median age of 45 years. Presenting symptoms were abdominal mass, pain, lower urinary tract symptoms, urinary retention and constipation. Imaging was mostly unable to determine the organ of origin of the tumour. Histopathology revealed pelvic fibromatosis (2), chondrosarcoma (1), liposarcoma (1), haemangioendothelioma (1), lymphangioma (2), fibroleiomyoma (1), leiomyosarcoma (3), schwannoma (4), malignant nerve sheath tumour (1), rectal gastrointestinal stromal tumour (1), retrovesical hydatid cysts (3), sacral chordoma (1) and Ewing’s sarcoma (1). In 5 patients complete excision was not possible because of extension into vital structures. Fifteen patients were alive at 1–5 years of follow-up. Conclusions: Urologists, being the ‘gatekeepers of the pelvis’, are usually involved in the management of large pelvic masses. Good outcome can be achieved with careful surgical planning.

show abstract

Thalidomide Inhibits the Growth and Progression of Hepatic Epithelioid Hemangioendothelioma

Cited by 59 publications

References 36 publications

Hepatic Epithelioid Hemangioendothelioma with Cecal Metastasis in a Natural Course: A Case Report

Hepatic Epithelioid Hemangioendothelioma with Cecal Metastasis in a Natural Course: A Case Report

Epithelioid Hemangioendothelioma of the Kidney Treated with Sunitinib

Large Pelvic Masses of Obscure Origin: Urologist’s Perspective

Contact Info

Product

Resources

About